Treatment Options for Tardive Dyskinesia

Author(s):

Jason Noel, PharmD, MPA, BCPP,Julie Dopheide, PharmD, BCPP, FASHP

Panelists discuss how VMAT2 inhibitors deutetrabenazine and valbenazine have revolutionized TD treatment through their proven efficacy in reducing involuntary movements and favorable safety profiles, with clinical trials demonstrating significant symptom improvement as measured by AIMS scores while maintaining psychiatric stability and showing key differences in dosing schedules and titration approaches.

EP: 1.Optimizing Tardive Dyskinesia Care: Strategies to Advance Treatment Approaches

EP: 2.Diagnosing Tardive Dyskinesia

EP: 3.Impact of Tardive Dyskinesia on Quality of Life

EP: 4.Improving Outcomes Through Patient Education and Addressing Unmet Needs

Now Viewing

EP: 5.Treatment Options for Tardive Dyskinesia

Video series above is prompted by the following:

Please provide an overview of the pharmacological treatment options currently available for patients with TD, highlighting their safety and efficacy.
Deutetrabenazine
Valbenazine